Cooper Laurence James Neil 4
4 · ZIOPHARM ONCOLOGY INC · Filed Dec 31, 2019
Insider Transaction Report
Form 4
Cooper Laurence James Neil
Chief Executive Officer
Transactions
- Sale
Common Stock
2019-12-30$4.88/sh−110,694$540,187→ 1,733,273 total - Exercise/Conversion
Common Stock
2019-12-27$2.24/sh+44,642$99,998→ 1,843,967 total - Exercise/Conversion
Employee Stock Option (right to buy)
2019-12-27−44,642→ 487,171 totalExercise: $2.24Exp: 2029-01-06→ Common Stock (44,642 underlying)
Footnotes (3)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person to satisfy withholding tax obligations upon the vesting of restricted stock grants.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.79 to $5.14, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]1/12th of the shares underlying this option will vest in equal quarterly installments commencing one quarterly period after 12/31/2018.